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Abstract Primary nocturnal enuresis is a prevalent childhood
condition that can persist into adulthood. Desmopressin is an
antidiuretic available as orally disintegrating lyophilisate
(melt) or solid tablet. Recent findings suggesting different food
interactions and clinical characteristics, including compliance,
between desmopressin melt and tablet motivated a post hoc
analysis of a previously reported randomised, crossover study.
The efficacy of desmopressin melt compared with tablet was
evaluated using the International Children’s Continence
Society (ICCS) responder definitions. Compliance was further
analysed using detailed criteria, and the association between
efficacy and compliance was examined. In total, 221 patients
aged 5–15 years, already receiving desmopressin tablets were
randomised to the treatment sequence melt (120/240 μg)/tablet
(0.2/0.4 mg) or tablet/melt in two consecutive 3-week periods.
The probability of being a responder (partial or full) during
either period was significantly more likely with desmopressin
melt compared with tablet (odds ratio, 2.0; confidence inter-
vals, 1.07–3.73; p=0.03). There was no period effect on com-
pliance in the tablet/melt sequence and no difference in the
number of completely compliant patients in each formulation
group; however, more patients were >75% compliant in period
1 compared with period 2 in the melt/tablet sequence.
Increased compliance was associated with greater reductions
in the number of wet nights for both formulations. Conclusions:
Desmopressin melt, compared with tablet, improves the prob-
ability of being a responder. Switching from tablet to melt
formulation increased patient compliance. Increased compli-
ance was associated with increased efficacy. Switching to
desmopressin melt may benefit patients with suboptimal re-
sponses to desmopressin tablet.
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Introduction
Monosymptomatic nocturnal enuresis (MNE), bedwetting
without any other lower urinary tract symptoms (LUTS)
[10], is a distressing problem that affects 6–10 % of 7-year-
old children [5]. It has an annual spontaneous resolution rate
of approximately 10–15 % [5], but not all cases resolve
spontaneously. Nocturnal enuresis persists in up to 3 % of
adolescents [21] and 1 % of untreated adults [5]. Given the
huge impact of enuresis on self-esteem, quality of sleep,
performance at school and social and familial life [4, 15],
timely and adequate treatment is mandatory. Enuresis is es-
sentially caused by a mismatch between nocturnal bladder
capacity and the amount of urine produced during the night
in children or adults who do not awake from sleep in response
to a full bladder [5]. Nocturnal polyuria (NP), due to insuffi-
cient arginine vasopressin hormone release at night, is a major
cause of MNE [12].
There are only two first-line treatments ofMNE available, the
enuresis alarm and desmopressin, both of which have level 1
grade A recommendations from the International Consultation
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on Incontinence [14]. Desmopressin is a selective vasopressin
receptor type 2 agonist that retains the antidiuretic properties of
vasopressin without inducing pressor activity. Recent guidelines
recommend an individualised treatment based on parameters
obtained using a voiding diary to assess important factors, such
as whether nocturnal enuresis is monosymptomatic or present
with additional LUTS symptoms, and whether patients have NP
[17]. Amongst those with MNE with underlying NP,
desmopressin is the recommended therapy due to its antidiuretic
action [17]. However, despite a significant percentage of full
responders in trials, there exist subpopulations of patients that
are only partial responders or appear desmopressin resistant
[16]. Up to 60 % of patients demonstrate less than a 50 %
decrease in wet nights in trials [8].
Currently, two different formulations of desmopressin are
approved in the USA and most of Europe for the MNE
indication: oral tablet and orally disintegrating lyophilisate
tablet (melt). These two formulations have been shown to be
clinically bioequivalent at doses of 200/400 μg for the tablet
and 120/240 μg for the melt in comparative studies in
healthy young volunteers [data from unpublished clinical
trial]. Primary analysis of the clinical anti-enuretic effect of
the tablet and melt in the PALAT study (NCT00209261)
supported this bioequivalence [9].
Stimulated by clinical observations that some patients
with partial desmopressin response on the tablet benefitted
from a switch to the melt, De Guchtenaere et al. published
data from a pharmacodynamic study in children with enure-
sis, demonstrating superior antidiuretic effect and concen-
trating capacity with the melt 120 μg compared with the
bioequivalent 0.2 mg tablet [2]. The design of the study
involved a single-dose administration and a standardised
meal aimed to reflect more closely the clinical reality for
young children with enuresis who are likely not to take the
drug on an empty stomach. The study demonstrated that
more than 25 % of patients had a higher diuresis rate and
lower concentrating capacity with the tablet vs melt formu-
lation in the early response phase, and a statistically signif-
icant difference in diuresis was observed in the plateau
phase and in duration of action [2]. This suggests that
decreased food interaction might increase the bioavailability
of desmopressin administered as the melt formulation com-
pared with tablet due to mucosal absorption of the melt in
the oral cavity and oesophagus [11, 20].
These recent findings on the potential interference of
food administration and the indices of superior clinical
characteristics of the melt (in an artificial setting of a
single-dose pharmacodynamic study), as well as the impor-
tance of compliance, stimulated us to perform a post hoc
analysis of existing data from the only multiple dose com-
parative clinical study of desmopressin melt vs tablet in
children with nocturnal enuresis [9]. A comparative phar-
macodynamic assessment in terms of anti-enuretic effect
was undertaken, using clinical response rates as currently
recommended by the ICCS [10]. However, these data are
from patients already receiving desmopressin tablet at base-
line; thus, the responder analysis in this study examines
response rates to desmopressin in addition to responses
following 2 weeks of desmopressin therapy. We also
reanalysed compliance data using the more detailed compli-
ance criteria used by Van Herzeele et al. [16], and investi-
gated the relationship between efficacy and compliance.
While post hoc analyses are not as powerful as primary
analyses, ethical considerations led us to pursue this course
instead of setting up a new interventional study in children,
since relevant data had already been collected. The current
analyses also support power calculations for any prospective
study protocols in MNE.
Methods
Clinical data were derived from an open-label randomised
crossover study with daily doses of desmopressin melt and
desmopressin tablet in children and adolescents with prima-
ry MNE (ClinicalTrials.gov Identifier: NCT00209261 [9]).
The study was approved by the institutional review board or
ethics committee for each site, the Declaration of Helsinki
was followed, and informed consent was obtained from all
patients.
Patients
The study was conducted in children and adolescents aged
5–15 years, with monosymptomatic primary nocturnal en-
uresis (PNE) who had been on a stable dose of 0.2 or 2×
0.2 mg desmopressin tablet for at least 2 weeks. The use of
non-pharmacological therapy (e.g. bed alarms) for nocturnal
enuresis during the 60 days before the screening visit was
not permitted for study participants. Inclusion and exclusion
criteria are listed in full in Table 1.
Study design
The study design has been described in detail elsewhere [7,
9]. Briefly, following a 2-week screening treatment period
with 0.2 or 2×0.2 mg tablet, as defined by the clinician as
the appropriate therapeutic dose for the patient, patients
were randomised 1:1 to the sequence melt/tablet or
tablet/melt (Fig. 1). Oral desmopressin tablets were admin-
istered at the same dose as during the screening period, and
desmopressin melt was administered at claimed bioequiva-
lent doses (0.2/0.4 mg tablet=120/240 μg melt). The inten-
tion to treat dataset, reported in the analysis, included all
patients who had at least one post-randomisation assessment
recorded.
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Table 1 Inclusion and exclusion criteria
Number Inclusion criteria Exclusion criteria
1 Male or female, 5–15 years of age (inclusive; or according to the
minimum age as specified in the marketing authorisation in each
country)
Presence or history of organic urological disease, diurnal
urinary incontinence, diabetes insipidus, ongoing urinary
tract infection, clinically significant renal, hepatic,
gastrointestinal, pulmonary, cardiovascular,
endocrinological or neurological disease that would
interfere with evaluation
2 Primary monosymptomatic nocturnal enuretic subjects Ongoing systemic antibiotic use, use of diuretics or any drugs
affecting urinary concentration, or medical treatment for
hyperactivity
3 Stabilised (at least 2 weeks) on 0.2 or 2×0.2 mg desmopressin at
the screening visit
Use of any experimental drug or device during 30 days before
the screening visit
4 The subject was to have been free of diurnal symptoms such as
urgency, frequency (more than seven micturitions during
daytime), voiding postponement or infrequent voiding (less than
three voidings during daytime), discoordinated voiding (painful
voiding or weak stream) and/or day wetting (more than once a
week)
Use of non-pharmacological therapy (e.g. bed alarms) during
60 days before the screening visit
5 Female subjects must have been pre-menarchial or sexually
inactive. Otherwise, contraception had to be used and a negative
pregnancy test obtained
Abnormalities or disease in the oral cavity that might have
affected the release and absorption of desmopressin from the
oral lyophilisate formulation
6 Willing and able to comply with the protocol requirements for the
duration of the study
The subject was a smoker
7 Parents of the child must have voluntarily signed a written informed
consent agreement, after explanation of the nature and objectives
of the study and prior to any study specific procedure and prior to
treatment. It had to be thoroughly explained that the consent could
be withdrawn at any time without prejudice. The institutional
ethics committee (IEC) had to approve the informed consent
agreement
Was hypersensitive towards any component of the
investigational product
8 Where appropriate, participants were to assent to enrol in the study
(age of assent to be determined by IECs or be consistent with
local legal requirements)
The subject and/or the subject's parents had mental incapacity or
language barriers precluding adequate understanding or
cooperation
9 Had previously participated in this study
10 Was considered unsuitable by the investigator, for any other
reason, to participate in the study
Fig. 1 Study design. Patients
stabilised on 0.2 or 0.4 mg
desmopressin tablets entered a
2-week screening period.
Eligible patients were
randomised 1:1 to receive
melt or tablet for 3 weeks,
then switched to the alternative
formulation for 3 weeks
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Responder analysis
The incidence of bedwetting episodes was recorded daily on
diary cards. The mean incidence/week was calculated as the
mean value of all data recorded between week -2 and 0 for
period 0 (screening period), between week 0 and 3 (period 1),
and betweenweek 3 and 6 (period 2). The reduction in number
of wet nights compared to baseline (week 0) in period 1 and 2
was categorised according to the ICCS response rates, modi-
fied to reflect the non-treatment naive baseline: non-response
is defined as a 0–49 % decrease, partial response is defined as
a 50–89 % decrease, response is defined as a ≥90 % decrease
and full response is defined as a 100 % decrease or less than
one symptom occurrence monthly [10]. These modified cate-
gories from a baseline of desmopressin treatment reflect addi-
tional responses with time to desmopressin, with the exception
of full response that may reflect a stable response of <1
symptom occurrence per month. The response rate for period
1 and 2 was summarised as a function of treatment and dose.
Compliance rate
Treatment compliance was verified based on diary records and
by review of empty blisters and unused study medication.
Patients returned empty medication packages. Study drug
compliance was calculated as a percentage of the number of
doses taken as instructed in each study period. Compliance
was categorised as 100, >75–99, 50–75 and <50 %, in line
with a recent study of desmopressin compliance [16], and
compliance rate by treatment and dose was summarised.
Statistical analysis
Power calculations have been presented for this study previ-
ously [9]. In brief, allowing for a 10 % dropout rate, a sample
size of 200 subjects would yield 80 % power to detect a true
preference proportion as low as 61%. Statistical evaluation was
performed using Statistical Analysis Software (v9.2). The num-
ber and proportion of patients was summarised by responder
status (non-responder, partial responder, responder and full
responder) for the two different treatment sequences. The com-
pliance rate was categorised according to the following: miss-
ing, <50, 50–75, >75–99 and 100 %, and summarised with
number and proportion of patients for each treatment sequence.
The distribution of proportions was compared using chi-square
tests. The probability of having an amelioration (i.e. reduction
in bedwetting; defined as partial responder, responder or full
responder) during period 1 and 2 was analysed using a repeated
logistic regression model with terms for sequence, age, treat-
ment, dose group, period and a random factor for subject. Using
error variance from the logistic model, the odds ratio (OR) and
95 % confidence intervals (CI) of the overall treatment effect
(melt vs tablet) was estimated. The association between
compliance rate and response was explored using an analysis
of covariance (ANCOVA) model with terms for sequence, age,
treatment, dose group, treatment by dose group interaction,
compliance group, treatment by compliance group interaction,
period and a random factor for subject. Using error variance
from the ANCOVA model, the compliance by treatment effect
was estimated and reported with 95 % CI.
Results
Patient characteristics
A total of 236 patients fulfilled the inclusion criteria and
following screening, 221 patients were randomised initially
to receive melt (n=111) or tablet (n=110) formulation (Fig. 1).
Of the 221 patients randomised, 72 patients were in the low-
dose group (120 μg melt and 0.2 mg tablet) and 149 patients
were in the high-dose group (240 μg melt and 2×0.2 mg
tablet). The mean number of wet nights per week during
screening was 1.54±1.75 and 2.39±2.02 in the low- and
high-dose groups, respectively. For both groups, the minimum
incidence of wet nights per week was zero and the maximum
incidence was seven. The majority of enrolled patients were
male (71.6 %) and the mean age was 9.6±2.4 years.
Responder analysis
The probability of having an amelioration was significantly
greater for desmopressin melt compared with desmopressin
tablet as assessed by the repeated logistic regression model
(OR=2; 95 % CI, 1.07–3.73; Table 2). The dose of
desmopressin also significantly increased the probability of
amelioration, with an OR of 3.05 favouring the lower dose melt
120 μg/tablet (0.2 mg) compared with the higher dose melt
240 μg/tablet (0.4 mg; Table 2).
Approximately 80 % of the patients were non-responders,
with <49 % further decrease in symptoms with continuing
desmopressin treatment, after completing period 1 in both
Table 2 Responder analysis: repeated logistic regression model with








Sequence 0.75 0.37–1.53 0.4334
Age (1 year increase) 1.17 0.95–1.30 0.1795
Formulation (melt vs tablet) 2.00 1.07–3.73 0.0288*
Dose group (low vs high) 3.05 1.63–5.70 0.0005*
Period 3.04 1.61–5.72 0.0006*
*p≤0.05, statistically significant difference between groups
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sequences (Table 3). There were slightly more responders
during the first period in the melt (6.5 %) compared with
tablet (1.9%) group. In addition, there was a significant period
effect for both formulations (p=0.0006) with more full re-
sponders and fewer non-responders in period 2 compared with
period 1 (Tables 2 and 3). Increased time on desmopressin
therapy increased responders, irrespective of formulation.
Compliance rate
At least 60 % of the patients in treatment sequence
tablet/melt were 100 % compliant in both period 1 and 2
(Table 3). There was no difference in the distribution of
compliance rate between the two different periods among
the patients in this sequence (p=0.2734). A similar percent-
age of patients in the other treatment sequence, melt/tablet,
were 100 % compliant in both period 1 (57 %) and 2 (60 %).
However, significantly more of these patients were >75–99 %
compliant in period 1 (melt) than in period 2 (tablet; 40 vs
28 %, respectively; p=0.0425; Table 4).
Across formulations, the reduction in mean number of
wet nights/week was significantly greater for higher com-
pliance rate compared with lower compliance rate groups
(Fig. 2). However, the lower compliance rate groups had
very low patient numbers. Compliance of >75 % appeared
to be a natural cut-off level, since the only non-significant
comparison was between the two lower compliance groups
(<50 and 50–75 %; p=0.86).
Discussion
Bioequivalence of desmopressin melt 120 μg and desmopressin
tablet 0.2 mg is supported by studies in healthy volunteers [data
from unpublished clinical trial]. Primary analyses of the current
dataset, reported by Lottmann et al., not only confirmed the
bioequivalence of the formulations at these doses, but added
important data on the comparable safety profiles of desmopressin
melt and tablet [9]. The anti-enuretic effect is directly related to
antidiuretic effect and concentrating activity, at least in patients
with high nocturnal diuresis, so superior antidiuretic effect should
lead to fewer wet nights. We are aware that a secondary analysis
can never reach the statistical power of the primary analysis, but
it is unethical to perform another study in children when existing
data can be used to test for differential clinical effects of, and
compliance with, claimed bioequivalent doses of the two
formulations.
This analysis compared the clinical response achieved with
both desmopressin formulations using response groups as
advised by the ICCS [10]. However, it should be noted that,
to be eligible for inclusion in this study, patients were required
to have already been receiving desmopressin tablets (0.2 or
0.4 mg) for at least 2 weeks prior to screening. Response rates
reported are therefore only indicative of additional improve-
ment achieved during this study, not of overall reduction in
wet nights with desmopressin compared with frequency of
wet nights experienced pre-treatment. Overall, 18 % of pa-
tients at period 2 receiving desmopressin tablet or melt were
full responders with no wet nights and 13% achieved a partial
response (additional 50–89 % reduction in wet nights). The
incidence of non-responders was higher than that usually
reported in trials of desmopressin in MNE because the study
population was treated with desmopressin at baseline.
Analysis using the repeated logistic regression model, con-
trolling for sequence of treatments, age, treatments, dose
group and period, found that the probability of an amelioration
in bedwetting (partial responder, responder or full responder)
was significantly greater for patients receiving desmopressin
melt compared with desmopressin tablet, with an OR of 2.
This observation supports the theory that desmopressin melt
Table 3 Distribution of
responders by treatment
sequence
Period 1 Period 2 Change in responders
from period 1 to 2
n (%) n (%) %
Sequence tablet/melt
Full responder 3 (2.83) 23 (22.33) 19.5
Responder 2 (1.89) 0 (0) −1.89
Partial responder 17 (16.04) 14 (13.59) −2.45
Non-responder 84 (79.25) 66 (64.08) −15.17
Missing data 1 4
Sequence melt/tablet
Full responder 4 (3.74) 16 (15.53) 11.79
Responder 8 (7.48) 1 (0.97) −6.51
Partial responder 12 (11.21) 15 (14.56) 3.35
Non-responder 83 (77.57) 71 (68.93) 8.64
Missing data 1 5
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has an improved pharmacokinetic profile, due to reduced food
interaction resulting in less variation of desmopressin plasma
concentration, and an improved pharmacodynamic profile
compared with desmopressin tablet as recently reported [1, 2].
Importantly, desmopressin melt offers a preferable adminis-
tration method compared with desmopressin tablet [9]. The
avoidance of fluid intake with drug administration helps to
reduce the risk of water intoxication. This is important, espe-
cially in children with PNE, as swallowing 2 oz (60 mL) of
fluid with a tablet is equivalent to about a quarter of the
expected bladder capacity of a 7 year old [13]. This reduction
in fluid intake was confirmed in the study of Lottman et al.
where patients reported taking water (mean of 40 mL) with
13.1 % of desmopressin melt doses, compared with 76.9 % of
tablet doses [9]. Avoiding the need for fluid intake with
desmopressin administration is also likely to impact upon effi-
cacy. A study of the pharmacodynamic effects of desmopressin
nasal spray reported that urine concentration was reduced when
fluid was not restricted before desmopressin administration [3].
In the treatment sequence tablet/melt, no difference in
compliance rate between the two periods was observed (p=
0.2734); while in treatment sequence melt/tablet, significantly
more patients were >75 % compliant in period 1 (melt) than
period 2 (tablet). In our opinion, although this finding is based
on 16 patients reducing compliance by ≤75%when switching
from desmopressin melt to tablet compared with three patients
switching from tablet to melt, if similar compliance behaviour
occurs in a real-life setting, it is of real clinical importance.
The role of compliance is certainly underestimated in therapy
resistance or partial response. In a substudy of the DRIP study
[8], an international investigation of desmopressin tablet treat-
ment for 6 months or less in children with PNE, compliance
data were available on 723 patients [16]. During the initial
run-in phases, 81–91 % of patients ingested all medication.
However, this decreased to 77 and 71 % during the first and
second 3-month treatment periods, respectively. High treat-
ment compliance was associated with improved response and
a narrower CI, indicating a greater response consistency
achieved bymore consistent medication [16]. Evenwith a study
period of only 6 weeks in the present analysis, the same
decreasing compliance over time was seen in patients receiving
desmopressin tablet. It is notoriously difficult tomeasure patient
compliance accurately, in almost all therapy areas. In this study,
treatment compliance was verified based on diary records and
by review of empty blisters and unused study medication.
While this is an objective method of monitoring medication
intake, it is possible that medication was lost or even thrown
away, for example to attempt to demonstrate that investigators’
instructions had been followed [16]. These factors may lead
estimates of treatment compliance to be artificially inflated, and
compliance rates in study populations, as well as clinical prac-
tice, are likely to be even lower than indicated.
Difficulties of compliance assessment aside, there are no
studies with desmopressin tablet or melt available that have
corrected their results for compliance in the individual patient.
As the antidiuretic duration of action of desmopressin is limited
to and only desirable during the night hours after drug admin-
istration, a high degree of compliance is essential to ensure
consistent therapeutic effects [16]. However, the rapid pharma-
codynamic effect of desmopressin supports conclusions on the
efficacy of treatment in an individual compliant patient in
14 days [20]. Future research should include longer studies of
desmopressin melt in patients with MNE and diagnosed NP to
provide evidence of the long-term clinical benefit of
desmopressin therapy in MNE. The additional responders seen
Table 4 Compliance rates by treatment sequence
Compliance rate <50 % 50–75 % >75–99.9 % 100 % Missing Total
n (%) n (%) n (%) n (%) n (%) n (%)
Sequence tablet/melt (p=2.743)a
Period 1 (tablet) 2 (1.83) 3 (2.75) 38 (34.86) 66 (60.55) 0 (0.0) 109 (100)
Period 2 (melt) 1 (0.92) 1 (0.92) 36 (33.03) 67 (61.47) 4 (3.67) 109 (100)
Sequence melt/tablet (p=0.0425)a
Period 1 (melt) 1 (0.92) 2 (1.83) 44 (40.37) 62 (56.88) 0 (0.0) 109 (100)
Period 2 (tablet) 5 (4.59) 4 (3.67) 31 (28.44) 65 (59.63) 4 (3.67) 109 (100)
a Chi-square test of difference in distributions of proportions
Fig. 2 Comparison between compliance groups on the reduction in
mean number of wet nights, overall across formulations. *p≤0.05,
statistically significant difference between compliance groups
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in this study suggest that improved responses to desmopressin
therapy are observed with increasing time on treatment.
Another reason for partial or no response to desmopressin
treatment is that many studies enrol patients with only minimal
screening, often in primary care settings, or do not use the new
ICCS definitions [10] and fail to exclude patients with LUTS
symptoms [18] suggestive of non-monosymptomatic nocturnal
enuresis. The pharmacokinetics of desmopressin may also
contribute to the findings of refractory enuresis in some pa-
tients since it is an oligopeptide with low bioavailability that
may vary dependent on the administered formulation. Initial
studies with desmopressin in enuresis were performed with
the nasal spray, which had to be withdrawn from the market
due to side effects, likely related to unpredictable bioavailabil-
ity following absorption by the nasal mucosa [19].
The significant period effect in favour of greater efficacy
in period 2 (i.e. the last 3 weeks of the six treatment weeks),
might be a ‘learning’ effect. Whilst this is a clinical benefit,
it is also a recognised methodological disadvantage of the
crossover design, in which behaviour in the first period
cannot be nullified for period 2. In this case, there was
possibly a behavioural component, either by influences of
the investigator, the patients themselves, their parents or a
combination of these, reducing the number of wet nights
over time. A learning effect in the treatment of PNE with
desmopressin is sparsely described in the literature; howev-
er, Läckgren et al. showed that prolonged treatment with
desmopressin has a pronounced effect on enuresis, especial-
ly during the period immediately after treatment cessation
[6]. This finding deserves further exploration.
The significantly better response in patients receiving the
lower desmopressin doses compared with the higher doses
seems contrary to the intuitive expectation that a higher dose
would be more effective. However, the study population
comprised patients who had been on a stable dose level of
0.2 or 2×0.2 mg desmopressin tablet based on their clini-
cian’s prescription prior to inclusion rather than a
randomised assignment to dose. Thus, patients in the low-
dose group (0.2 mg desmopressin tablet) at screening were
probably highly polyuric patients with normal bladder ca-
pacity. In contrast, the patients prescribed the higher dose
likely contained a larger proportion of desmopressin non- or
partial responders. A potential weakness of our analysis is
that other covariates such as age, weight and gender could
correlate to final dose although former pharmacokinetic
modelling showed that no such tested covariates provided
a statistically significant model improvement [11].
Clinical implications
This study shows that the probability of having a reduction in
bedwetting episodes is increased by a factor of two for patients
receiving desmopressin melt compared with desmopressin
tablet. Thus, for patients with a suboptimal response to
desmopressin tablets, there may be a clinical benefit to
switching to desmopressin melt. As the antidiuretic effects
of desmopressin tablet and melt are maintained for 6–11 h
[5, 20] a high degree of compliance is essential to ensure
consistent therapeutic effects. This study demonstrates that
significantly better compliance is obtained with desmopressin
melt, when switching from the tablet to melt formulation,
which may partially explain the increased probability of hav-
ing a reduction in bedwetting episodes for patients receiving
desmopressin melt compared with tablet. Although the melt
formulation is more expensive than the tablet in most coun-
tries, the reduction in bedwetting episodes results in savings in
terms of laundry or diaper costs. Our findings are supportive
of recent findings of better pharmacokinetic and pharmacody-
namic characteristics for desmopressin melt compared with
tablet [1, 2]. Additional exploration of predictors of clinical
response may further optimise the dosage regimen of
desmopressin in an individual PNE patient.
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